FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285404799> ?p ?o ?g. }

• W4285404799 endingPage "1070" @default.
• W4285404799 startingPage "1061" @default.
• W4285404799 abstract "No standard of care for mucosal melanoma (MM) in the adjuvant setting has been established. Meanwhile, relapse-free survival (RFS) is only ∼5 months after surgery alone. This phase II trial aimed to compare toripalimab versus high-dose interferon-α2b (HDI) as an adjuvant therapy for resected MM.From July 2017 to May 2019, 145 patients with resected MM were randomized (1 : 1) to receive HDI (n = 72) or toripalimab (n = 73) for 1 year until disease relapse/distant metastasis, unacceptable toxicity, or withdrawal of consent. The primary endpoint was RFS. The secondary endpoints included distant metastasis-free survival (DMFS), overall survival (OS), and safety.After a median follow-up of 26.3 months, the number of RFS, OS, and DMFS events was 51 versus 46, 33 versus 29, and 49 versus 44 in the toripalimab arm and the HDI arm, respectively. The median RFS was 13.6 [95% confidence interval (CI) 8.31-19.02] months and 13.9 (95% CI 8.28-19.61) months in the toripalimab arm and the HDI arm, respectively. The DMFS was not significantly different between the two arms [hazard ratio (HR) 1.00; 95% CI 0.65-1.54]. The median OS was 35.1 months (95% CI 27.93 months-not reached) in the toripalimab arm, with no significant difference in all-cause death (HR 1.11, 95% CI 0.66-1.84) for the two arms. The median sums of the patients' actual infusion doses were 3672 mg and 1054.5 MIU in the toripalimab arm and the HDI arm, respectively. The incidence of treatment-emergent adverse events with a grade ≥3 was much higher in the HDI arm than in the toripalimab arm (87.5% versus 27.4%).Toripalimab showed a similar RFS and a more favorable safety profile than HDI, both better than historical data, suggesting that toripalimab might be the better treatment option. However, additional translational studies and better treatment regimens are still warranted to improve the clinical outcome of MM." @default.
• W4285404799 created "2022-07-14" @default.
• W4285404799 creator A5007562507 @default.
• W4285404799 creator A5009201250 @default.
• W4285404799 creator A5012351800 @default.
• W4285404799 creator A5018372804 @default.
• W4285404799 creator A5028690121 @default.
• W4285404799 creator A5035059972 @default.
• W4285404799 creator A5035685296 @default.
• W4285404799 creator A5047774145 @default.
• W4285404799 creator A5054050281 @default.
• W4285404799 creator A5055356574 @default.
• W4285404799 creator A5062012068 @default.
• W4285404799 creator A5062637798 @default.
• W4285404799 creator A5064635462 @default.
• W4285404799 creator A5067601329 @default.
• W4285404799 creator A5068116429 @default.
• W4285404799 creator A5068605395 @default.
• W4285404799 creator A5069813415 @default.
• W4285404799 creator A5069921367 @default.
• W4285404799 creator A5085312120 @default.
• W4285404799 creator A5087476818 @default.
• W4285404799 date "2022-10-01" @default.
• W4285404799 modified "2023-10-18" @default.
• W4285404799 title "Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial" @default.
• W4285404799 cites W1970051943 @default.
• W4285404799 cites W1990435553 @default.
• W4285404799 cites W2040634773 @default.
• W4285404799 cites W2068237418 @default.
• W4285404799 cites W2097691839 @default.
• W4285404799 cites W2118449798 @default.
• W4285404799 cites W2121637902 @default.
• W4285404799 cites W2167925208 @default.
• W4285404799 cites W2563871566 @default.
• W4285404799 cites W2606158620 @default.
• W4285404799 cites W2752227448 @default.
• W4285404799 cites W2797309423 @default.
• W4285404799 cites W2799502945 @default.
• W4285404799 cites W2964599082 @default.
• W4285404799 cites W2967113395 @default.
• W4285404799 cites W2991335898 @default.
• W4285404799 cites W3025788043 @default.
• W4285404799 cites W3087697977 @default.
• W4285404799 cites W3089892480 @default.
• W4285404799 cites W3153228158 @default.
• W4285404799 cites W3190270536 @default.
• W4285404799 cites W3208828613 @default.
• W4285404799 cites W4242090516 @default.
• W4285404799 doi "https://doi.org/10.1016/j.annonc.2022.07.002" @default.
• W4285404799 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35842199" @default.
• W4285404799 hasPublicationYear "2022" @default.
• W4285404799 type Work @default.
• W4285404799 citedByCount "12" @default.
• W4285404799 countsByYear W42854047992022 @default.
• W4285404799 countsByYear W42854047992023 @default.
• W4285404799 crossrefType "journal-article" @default.
• W4285404799 hasAuthorship W4285404799A5007562507 @default.
• W4285404799 hasAuthorship W4285404799A5009201250 @default.
• W4285404799 hasAuthorship W4285404799A5012351800 @default.
• W4285404799 hasAuthorship W4285404799A5018372804 @default.
• W4285404799 hasAuthorship W4285404799A5028690121 @default.
• W4285404799 hasAuthorship W4285404799A5035059972 @default.
• W4285404799 hasAuthorship W4285404799A5035685296 @default.
• W4285404799 hasAuthorship W4285404799A5047774145 @default.
• W4285404799 hasAuthorship W4285404799A5054050281 @default.
• W4285404799 hasAuthorship W4285404799A5055356574 @default.
• W4285404799 hasAuthorship W4285404799A5062012068 @default.
• W4285404799 hasAuthorship W4285404799A5062637798 @default.
• W4285404799 hasAuthorship W4285404799A5064635462 @default.
• W4285404799 hasAuthorship W4285404799A5067601329 @default.
• W4285404799 hasAuthorship W4285404799A5068116429 @default.
• W4285404799 hasAuthorship W4285404799A5068605395 @default.
• W4285404799 hasAuthorship W4285404799A5069813415 @default.
• W4285404799 hasAuthorship W4285404799A5069921367 @default.
• W4285404799 hasAuthorship W4285404799A5085312120 @default.
• W4285404799 hasAuthorship W4285404799A5087476818 @default.
• W4285404799 hasBestOaLocation W42854047991 @default.
• W4285404799 hasConcept C126322002 @default.
• W4285404799 hasConcept C141071460 @default.
• W4285404799 hasConcept C168563851 @default.
• W4285404799 hasConcept C203092338 @default.
• W4285404799 hasConcept C207103383 @default.
• W4285404799 hasConcept C2776694085 @default.
• W4285404799 hasConcept C2777658100 @default.
• W4285404799 hasConcept C2777863537 @default.
• W4285404799 hasConcept C2777982462 @default.
• W4285404799 hasConcept C29730261 @default.
• W4285404799 hasConcept C31760486 @default.
• W4285404799 hasConcept C44249647 @default.
• W4285404799 hasConcept C502942594 @default.
• W4285404799 hasConcept C71924100 @default.
• W4285404799 hasConcept C90924648 @default.
• W4285404799 hasConceptScore W4285404799C126322002 @default.
• W4285404799 hasConceptScore W4285404799C141071460 @default.
• W4285404799 hasConceptScore W4285404799C168563851 @default.
• W4285404799 hasConceptScore W4285404799C203092338 @default.
• W4285404799 hasConceptScore W4285404799C207103383 @default.
• W4285404799 hasConceptScore W4285404799C2776694085 @default.

• next